First report of monepantel Haemonchus contortus resistance on sheep farms in Uruguay

A farmer in Uruguay checks on his lambs nine days after a routine deworming treatment. The drug is supposed to knock out parasites fast — egg counts should have collapsed. Instead, they haven't moved. Some lambs are dying. The drug that was intended to be the last line of defense has stopped working. What makes this alarming isn't just the dead lambs. It's that monepantel — the drug that failed — was brand new and belonged to a completely different chemical class. Resistance was not supposed to arrive this quickly. To understand why that matters, you need to know how bad things already were. Mederos and colleagues describe a Uruguayan sheep sector that had spent decades watching anthelmintics fail one by one. A national survey in nineteen ninety-four and nineteen ninety-five found benzimidazole resistance on eighty percent of farms and levamisole resistance on seventy-one percent. By a two thousand five sample of one hundred thirty farms, ivermectin resistance had reached eighty-nine percent, closantel eighty-nine percent, levamisole eighty-two percent, and even the newer moxidectin had failed on twenty-nine percent of farms. Haemonchus and Trichostrongylus were the main culprits throughout. In that context, the arrival of monepantel — an amino-acetonitrile derivative, or AAD, with a mechanism of action that no worm had ever encountered — felt like genuine relief. It became commercially available in Uruguay in two thousand ten. By two thousand fourteen, it was already failing. Mederos, Ramos, and Banchero detected the failure on two research farms run by INIA, Uruguay's national agricultural institute. On both farms, routine monepantel treatments had not reduced fecal egg counts the way they should have, and lamb mortality from Haemonchus contortus infection followed. To confirm what they suspected, they ran a Fecal Egg Count Reduction Test, or FECRT — the field-standard method for measuring whether an anthelmintic drug actually suppresses worm egg output in a flock. They followed World Association for the Advancement of Veterinary Parasitology, or WAAVP, guidelines to ensure their results would be directly comparable to other studies. The core calculation, described by Dash in nineteen eighty-eight, is straightforward: percent reduction equals one hundred times one minus the ratio of the treated group's mean egg count to the control group's mean egg count. Confidence intervals were derived from the BootStreat program. The two-farm design was careful. Farm one, at INIA Tacuarembó, used six to eight month old Corriedale and Merino Dohne cross lambs divided into three groups of fifteen each: an untreated control, a group treated with monepantel sourced previously, and a group treated with monepantel from stock provided fresh by the supplier. That third group was a deliberate check — if both stocks failed equally, a bad vial wouldn't explain it. Treatments were administered orally at the recommended two point five milligrams per kilogram of body weight. Fecal samples were collected on day zero and day nine. Farm two, at INIA La Estanzuela, used eight month old Milchschaf cross lambs, ten treated and ten untreated controls, following the same sampling protocol. The numbers that came back were stark. On Farm one, the control group's mean egg count rose from three thousand three hundred seven to five thousand four hundred ninety eggs per gram — worms multiplying unchecked, as expected in untreated animals. The first treated group, given the previously purchased stock, started at three thousand twenty eggs per gram and ended at five thousand one hundred thirty-two. Fecal egg count reduction: zero percent. The ninety-five percent confidence interval ranged from zero to forty-nine percent, indicating total failure and statistically consistent with no effect at all. The second treated group, given the supplier's fresh stock, went from five thousand one hundred seventeen to five thousand one hundred fourteen eggs per gram. The reported reduction was forty-two percent, with a confidence interval ranging from zero to seventy-five percent. This sounded better, but the lower bound again touches zero. On Farm two, the treated group dropped from two thousand eight hundred eighty to four hundred seventy-five eggs per gram — a reduction of eighty-two point one percent, with a confidence interval of thirty-six to ninety-nine percent. That was the best result of the three, and it was still below the WAAVP threshold for adequate efficacy. Every result, on both farms, with both drug stocks, fell short. Coproculture — culturing fecal samples to identify which worm species are present — sharpened the picture further. In the post-treatment samples from monepantel-treated groups on Farm one, Haemonchus species made up one hundred percent of recovered larvae. On Farm two, it was ninety-three percent. The drug hadn't cleared these animals. The worms that survived were overwhelmingly Haemonchus. That is the fingerprint of resistance in that genus. So how did resistance emerge this fast? Monepantel had been on the Uruguayan market for roughly four years. Mederos and colleagues lay out two overlapping explanations, though they're careful about what their retrospective data can and can't prove. The first is genetic: previous research had demonstrated an AAD mutant gene present in a sub-population of Haemonchus contortus. The field failures on these two farms are compatible with the phenotypic expression of that gene. Confirming it would require molecular analysis of isolates from the coprocultures and adult worms — work that was not done in this report, but that the paper explicitly calls for. The second explanation involves management. Conventional resistance thinking points to high treatment frequency and low refugia — refugia being the portion of the worm population that remains unexposed to drugs and therefore dilutes resistant genes when it breeds with survivors. If you treat every animal repeatedly, you eliminate that buffer. The two farms differed here in a telling way. On Farm one, monepantel use began in two thousand eleven with whole-flock treatments, then in two thousand thirteen escalated to three treatments covering all lambs and all ewes. That's the pattern most often linked to resistance selection. On Farm two, treatments were applied as targeted selective treatment guided by routine FAMACHA scoring — a system for identifying the most anemic animals — and only five to ten percent of the flock was treated at any given time. That should, in theory, preserve refugia. Yet resistance appeared on Farm two as well. Mederos and colleagues are honest about this tension. They conclude that the conventional risk factors "do not seem to be important here," but add that paddock management on both farms was complex enough that retrospective unbiased causal conclusions simply couldn't be drawn. It's a reminder that field research operates in messier conditions than controlled experiments and that resistance can arrive through routes that don't fit the textbook narrative neatly. What makes the Uruguayan finding feel less like a local accident and more like a signal is the parallel with New Zealand. Monepantel was licensed in New Zealand in two thousand nine; resistance was reported there in two thousand thirteen. Uruguay licensed it in two thousand ten; resistance was detected in two thousand fourteen. Four years in both cases. The paper is explicit: this is not an isolated national problem. It's a pattern. The call to action from Mederos and colleagues is specific. Molecular studies are needed to confirm the AAD mutation in the Haemonchus isolates from these farms. Detection tools beyond the Fecal Egg Count Reduction Test — methods that can identify resistance before treatment failures become visible — need to be developed and deployed. Roeber and colleagues are cited as having recently proposed approaches in this direction. The goal is to catch resistance early before resistant worms spread farm to farm and close off the last chemical option available to Uruguayan sheep producers. The window is not wide. Uruguay's sheep sector has already lost benzimidazoles, levamisole, ivermectin, and closantel to widespread resistance. Moxidectin is compromised on nearly a third of farms. Monepantel was the new class, the one with no prior exposure, the one that was supposed to buy time. If the four-year pattern holds, and if molecular confirmation bears out what the fecal egg counts already suggest, then the window for managing this — for keeping refugia, for tracking resistance alleles, for coordinating across farms — is not years away. It's now. This lecture was created by ennepō. Go to https://ennepo.ai to Discover, Create and Follow the latest research in your field. Read when you can. Listen when you want to.